MILAN, ITALY--(Marketwire - April 24, 2012) - Recordati announces the acquisition of the
marketing
authorizations, the trademarks and additional assets concerning six
OTC
pharmaceuticals for Germany from Cilag GmbH International and McNeil GmbH
& Co.
oHG. The products acquired are JHP-Rödler® (mint oil
indicated for digestive
disorder, headache, cough and cold), Betadorm® D (Diphenhydramine HCl
indicated
for sleep disorders), Rhinopront® (pseudoephedrine+triprolidine
indicated for
rhinitis and head colds), Collomack® Topical (salicylic acid
solution, an anti-
corn preparation), Tirgon® (bisacodyl for constipation) and
Xitix® (vitamin C
lozenges to treat vitamin C deficiency). Estimated 2012 sales for
the six
products are of around EUR 6 million.
"The acquisition by our German subsidiary of these six well known
brands
represents an interesting opportunity to strengthen Recordati
Pharma's OTC
product portfolio", declared Giovanni Recordati, Chairman and CEO
of the
Recordati Group. "The OTC pharmaceutical segment in Germany is worth around
EUR 4
billion and represents a share in units of 52% of the overall
pharmaceutical
market. Together with the existing OTC portfolio, which includes well
known
brands such as Mirfulan®, Osteoplus®, Dolobene®,
Flosa® and Silibene®, the
German subsidiary is now able to better exploit the OTC market
potential by
building a dedicated sales organization".
Recordati, established in 1926, is a European pharmaceutical group,
listed on
the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM,
ISIN IT
0003828271), with a total staff of over 3,200, dedicated to the
research,
development, manufacturing and marketing of pharmaceuticals. It has
headquarters
in Milan, Italy, operations in the main European countries, and a
growing
presence in the new markets of Central and Eastern Europe. A European
field
force of around 1,700 medical representatives promotes a wide
range of
innovative pharmaceuticals, both proprietary and under license, in a
number of
therapeutic areas including a specialized business dedicated to
treatments for
rare diseases. Recordati's current and growing coverage of the
European
pharmaceutical market makes it a partner of choice for new product licenses
from
companies which do not have European marketing organizations.
Recordati is
committed to the research and development of new drug entities
within the
cardiovascular and urogenital therapeutic areas and of treatments for
rare
diseases. Consolidated revenue for 2011 was EUR 762.0 million, operating
income
was EUR 163.5 million and net income was EUR 116.4 million.
Statements contained in this release, other than historical facts, are
"forward-
looking statements" (as such term is defined in the Private
Securities
Litigation Reform Act of 1995). These statements are based on
currently
available information, on current best estimates, and on assumptions
believed to
be reasonable. This information, these estimates and assumptions may prove
to be
incomplete or erroneous, and involve numerous risks and uncertainties,
beyond
the Company's control. Hence, actual results may differ materially from
those
expressed or implied by such forward-looking statements. All
mentions and
descriptions of Recordati products are intended solely as information
on the
general nature of the company's activities and are not intended to
indicate the
advisability of administering any product in any particular instance.
Recordati acquires six OTC products in Germany:
http://hugin.info/143644/R/1605393/508401.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: RECORDATI via Thomson Reuters ONE
[HUG#1605393]
